Navigation Links
Drug companies in India keen on developing bird flu drug

The government is likely to invoke the compulsory licensing (CL) provision in the Patents Act that would enable domestic drug //firms to produce and stockpile Swiss drug maker Roche’s patented drug Tamiflu, useful in combating the global threat against the most dreaded avian flu virus.

Section 92 empowers the government to issue CL without receipt of an application from the industry. Furthermore, the issue of such license is independent of third party consent. The following proposal is expected to help cope up with a public health emergency that might arise in case the pandemic hits India. Once compulsory licensing has been issued, manufacture of the drug can be initiated, to ensure both domestic and international supply.

The drug companies in India are more than willing to participate in the initiative. Ranbaxy Laboratories has already initiated talks with the Swiss pharma company regarding the issue. The company is also getting in touch with governments across the world, interested in sourcing the drug from it.

The situation would however require a critical analysis of patents issue across the world. It would be six months before the drug can actually be manufactured following regulatory approvals.

In response to the above situation, Roche has announced it would not welcome interventions by generic drug makers in Tamiflu market, the demand for which has increased manifold following reports that the pandemic has reached Europe and SE Asia.

Medindia on Bird Flu:

Avian influenza (AI) or Bird Flu is a disease of viral etiology that ranges from a mild or even asymptomatic infection to an acute, fatal disease of chickens, turkeys, guinea fowls, and other avian species, especially migratory waterfowl
'"/>




Page: 1

Related medicine news :

1. India to benefit from pharma companies move
2. Doctors not to accept gifts from drug companies
3. Pharmaceutical companies are targeting patients
4. Historic trial for tuberculosis launched together by leading drug companies
5. Pakistan drug companies seek trade ties with India
6. Depression Accompanies Heart Attacks in Younger Women
7. Cigarette companies adopt devious methods to ensure customer patronage
8. Is Diabetes the Leading Cause of Kidney Failure in India
9. AIDS Disaster in India is Imminent
10. Indian Prime Minister has successful Knee Replacement Surgery
11. International community warns India on HIV situation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: